QTTB Q32 Bio Inc. Common Stock Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:15
Jul 13
Jul 13
The author dismisses QTTB's data as fake and open-label bullshit.
The author dismisses QTTB's data as fake and open-label bullshit, expressing skepticism without taking a directional position.
LOW
11:34
Jun 10
Jun 10
Q32 safety risky; competition overblown.
Q32 Bio's drug targets IL-7, a pathway where human mutations cause severe immunodeficiency called SCID, often fatal, creating significant safety concerns. Its alopecia areata data is open-label and may look better than blinded data, while its blinded efficacy was worse than Nektar's. Management has a history of hyping data and disappointing, including a failed atopic dermatitis study. Adam is not worried about it as a Nektar competitor, implying investors should avoid Q32.
MED
About QTTB Investor Commentary
Across the available history and selected sources, Buzzberg tracks QTTB (Q32 Bio Inc. Common Stock) across 2 sources: 0 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: Martin Shkreli, A May MD.